Uehara Tomoya

ウエハラトモヤ | Uehara Tomoya

Affiliation and department：
Job title： Professor
Homepage URL (1)： https://www.p.chiba-u.jp/lab/housha/

Research field (1)： Pharmaceuticals - analytical and physicochemistry

Research keywords (2)：放射性医薬品 , Radiopharmaceutical

Research theme for competitive and other funds (31)：

2022 - 2027 多価効果と代謝性リンカーの融合による革新的核医学治療薬の開発
2023 - 2026 ラジオハロゲン元素を用いた前立腺がんに対するラジオセラノスティクス薬剤の開発
2022 - 2025 セラノスティクスを目的とした放射性標識ソマトスタチンアナログの体内動態の最適化
2022 - 2025 繊維芽細胞活性化タンパク質を標的としたアスタチン-211標識薬剤の開発
2020 - 2023 腎放射活性を低減するradiotheranostic薬剤の新規設計

2018 - 2021 液体合金標的で拓く有用RIの2核種同時製造・標識法の開発

2017 - 2020 Development of radiotheranostics agent using Fab fragment of anti-regulatory T cells

2014 - 2017 Development of highly-sensitive apoptosis imaging agent based on new drug design

2014 - 2016 Development of dual-modality SPECT/fluorescent probe

2013 - 2016 Engineering radiolabeled antibody fragments for enhanced tumor to kidney ratio

2011 - 2012 99mTc-labeled probes imitating antibodies

2010 - 2012 Development of radiolabeled antibody for channel transporter imaging

2009 - 2010 Design of ^<99m>Tc-labled compound for diagnosis of metastatic tumor in bone

2008 - 2009 がん集積の向上を目指す標識抗体の新規設計法

2007 - 2008 In vivo imaging of DNA repair for estimating the sensitivity of tumor to radiotherapy

2007 - 2008 Near infrared imaging of indocyanine green for sentinel lymph node navigation using nano-sized particle

2006 - 2008 Chemical design of chelating agents suitable to radiotherapy using antibody fragments as vehicles

2006 - 2007 標的分子との高い結合力を有する多価テクネチウム標識薬剤の設計

2005 - 2007 DEMELOPMENT OF RAKIOLABELED SMALLER ANTI-TENASCIN-CANTIBODY FOR CLINICAL USE

2005 - 2006 エネルギー依存性アミノ酸輸送システム評価薬剤は癌治療効果の早期判定に有効か

2005 - 2006 Sentinel lymph node mapping using 99m Tc-labeled mannosyl-neoglycoalbumin and small semiconductor gamma camera for gastrointestinal cancers.

2003 - 2004 癌治療効果の早期判定を目的とする放射性薬剤の開発

2003 - 2004 アイソトープ治療の副作用低減と治療効果増強を目的とした金属RI標識ペプチドの設計

2002 - 2004 Molecular design of radioiodinated peptides for targeted radiotherapy

2001 - 2002 骨代謝機能診断および転移性骨腫瘍の疼痛緩和を目的とする放射性薬剤の設計

2001 - 2002 放射能の核移行を目的としたタンパク質標識試薬の開発

2000 - 2002 DEVELOPEMENT OF RADIOIODINATED RADIOPHARMACEUTICALS FOR INTERNAL RADIATION THERAPY OF TUMOR BASED ON ITS SPECIFIC METABOLIC ACTIVITY

癌の内用放射線治療に有効な放射能送達の化学的制御

ジスルフィド結合を有する抗腫瘍環状ペプチドRC-160のTC-99m標識

Delivery of radio iodinated peptides for internal radiotherapy

The Integrity of the Disaltiole Bond in a Cyclic Somstostatin Anulog during ^99mTC Complexation Reactions

Show all

Papers (85)：

Masatoshi Tada, Yuta Kaizuka, Kento Kannaka, Hiroyuki Suzuki, Taiki Joho, Kazuhiro Takahashi, Tomoya Uehara, Hiroshi Tanaka. Development of a neopentyl 211At-labeled activated ester providing in vivo stable 211At-labeled antibodies for targeted alpha therapy. ChemMedChem. 2024
Hiroyuki Suzuki, Masato Matsukawa, Rikako Madokoro, Yui Terasaka, Kento Kannaka, Tomoya Uehara. Reduction of the hepatic radioactivity levels of [111In]In-DOTA-labeled antibodies via cleavage of a linkage metabolized in lysosomes. Nuclear Medicine and Biology. 2024. 132-133. 108910
Hiroyuki Suzuki, kento kannaka, Tomoya Uehara. Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies. Pharmaceuticals. 2024
Masatoshi Tada, Yuta Kaizuka, Kento Kannaka, Hiroyuki Suzuki, Taiki Joho, Kazuhiro Takahashi, Tomoya Uehara, Hiroshi Tanaka. Resin-assisted synthesis of a neopentyl 211At-labeled activated ester possessing a triazole spacer and its application to the synthesis of in vivo stable 211At-labeled antibodies. 2024
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, et al. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 17-17

ｍore...

MISC (7)：

小池悠介, 小池悠介, 梅田泉, 木村禎亮, 東顕二郎, 上原知也, 森部久仁一, 荒野泰, 山本恵司, 藤井博史. 網内系集積の低減と腫瘍特異性向上を目指した⁹⁹mTc及び¹¹¹In封入リポソームの開発. 核医学. 2011. 48. 3. S245-S245
Y Arano, Y Fujioka, S Satake, T Uehara, H Saji. Evidences for renal brush border enzymesmediated release of iodohippuric acid from 3-iodohippuryl-N-e-maleoyl-L-lysine conjugated antibody fragments. JOURNAL OF NUCLEAR MEDICINE. 2003. 44. 5. 305P-305P
藤岡泰, 荒野泰, 向高弘, 秋澤宏行, 上原知也, 小川数馬, 佐治英郎. 腫瘍選択的な放射能送達を可能とするRI標識抗体フラグメントの開発. 薬物動態 = Xenobiotic metabolism and disposition. 2001. 16. S265
UEHARA T. Approaches for reducing the renal radioactivity levels of antibody fragments. Biomedical research on trace elements. 2001. 12. 2. 152-158
UEHARA Tomoya, FUJIOKA Yasushi, SAJI Hideo, ARANO Yasushi. Development of Radiopharmaceuticals for Targeted Radiotherapy of Tumor. 2000. 11. 4. 353-354

ｍore...

Lectures and oral presentations (4)：

211At標識化合物の開発
(日本アイソトープ協会シンポジウム 2021)
Radiometal-labeling agents of antibody fragments for low renal radioactivity levels
(CSPS/PSJ/CC-CRS 2021 SYMPOSIUM 2021)
非特異的腎集積を低減する放射性ガリウム/銅を用いた抗体フラグメント標識薬剤に関する研究
(核医学診断・治療のためのRI利用シンポジウムー64Cu・67Cu:核種構造と治療薬剤創製の展望ー 2021)
腎放射活性の低減を目的としたCu-64標識薬剤の開発
(日本分子イメージング学会 2021)

Work history (1)：

2019/10 - 現在千葉大学大学院薬学研究院教授

Association Membership(s) (3)：

日本核医学会 , 日本薬学会 , 日本分子イメージング学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page